IOBT Insider Trading
Insider Ownership Percentage: 4.80%
Insider Buying (Last 12 Months): $39,482.50
Insider Selling (Last 12 Months): $0.00
IO Biotech Share Price & Price History
Current Price: $0.68
Price Change: ▲ Price Increase of +0.0369 (5.75%)
As of 12/4/2025 05:00 PM ET
IO Biotech Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/30/2025 | Heidi Hunter | Director | Buy | 15,000 | $1.39 | $20,850.00 | 15,000 |  |
| 12/23/2024 | Amy Sullivan | CFO | Buy | 10,250 | $0.83 | $8,507.50 | 84,632 | |
| 12/23/2024 | Mai-Britt Zocca | CEO | Buy | 12,500 | $0.81 | $10,125.00 | 49,891 | |
| 7/25/2024 | Holdings A/S Novo | Major Shareholder | Sell | 51,522 | $1.33 | $68,524.26 | 4,377,927 | |
| 5/10/2024 | Holdings A/S Novo | Major Shareholder | Sell | 658,809 | $1.22 | $803,746.98 | 4,429,449 | |
| 2/9/2024 | Holdings A/S Novo | Major Shareholder | Sell | 658,809 | $1.50 | $988,213.50 | 5,088,258 | |
| 11/21/2023 | Brian Burkavage | CAO | Buy | 5,000 | $0.99 | $4,950.00 | 6,500 | |
| 8/9/2023 | Vivo Capital Ix, Llc | Major Shareholder | Buy | 3,157,894 | $1.90 | $5,999,998.60 | 3,157,894 | |
| 3/17/2023 | Amy Sullivan | CFO | Buy | 25,000 | $2.32 | $58,000.00 | 25,000 | |
IO Biotech Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 11/17/2025 | Novo Holdings A S | 2,512,453 | $0.91M | 0.1% | -25.1% | 3.814% |  |
| 11/17/2025 | Millennium Management LLC | 1,392,396 | $0.51M | 0.0% | N/A | 2.114% | |
| 11/17/2025 | Bank of America Corp DE | 799,953 | $0.29M | 0.0% | -50.5% | 1.214% | |
| 11/17/2025 | Boothbay Fund Management LLC | 591,180 | $0.22M | 0.0% | N/A | 0.897% | |
| 8/19/2025 | Marex Group plc | 45,000 | $63K | 0.0% | N/A | 0.000% | |
| 8/15/2025 | Bank of America Corp DE | 1,615,074 | $2.25M | 0.0% | -2.2% | 0.000% | |
| 8/14/2025 | NewEdge Advisors LLC | 24,217 | $34K | 0.0% | N/A | 0.037% | |
| 8/12/2025 | XTX Topco Ltd | 29,189 | $41K | 0.0% | -42.2% | 0.000% | |
| 5/21/2025 | Acadian Asset Management LLC | 30,858 | $33K | 0.0% | -49.1% | 0.047% | |
| 5/19/2025 | Jane Street Group LLC | 23,717 | $26K | 0.0% | N/A | 0.036% | |
| 5/15/2025 | Landscape Capital Management L.L.C. | 400,234 | $0.44M | 0.0% | -9.5% | 0.608% | |
| 5/8/2025 | XTX Topco Ltd | 50,486 | $55K | 0.0% | +80.0% | 0.077% | |
| 5/7/2025 | Dauntless Investment Group LLC | 681,446 | $0.74M | 0.9% | -8.9% | 1.034% | |
| 2/17/2025 | Bridgeway Capital Management LLC | 174,000 | $0.16M | 0.0% | -12.8% | 0.264% | |
| 2/17/2025 | Citadel Advisors LLC | 270,504 | $0.25M | 0.0% | N/A | 0.411% | |
| 2/14/2025 | Dauntless Investment Group LLC | 747,646 | $0.69M | 0.7% | N/A | 1.135% | |
| 2/13/2025 | XTX Topco Ltd | 28,040 | $26K | 0.0% | N/A | 0.043% | |
| 2/13/2025 | Renaissance Technologies LLC | 118,800 | $0.11M | 0.0% | +22.5% | 0.180% | |
| 2/12/2025 | Landscape Capital Management L.L.C. | 442,196 | $0.41M | 0.0% | N/A | 0.671% | |
| 1/30/2025 | Vontobel Holding Ltd. | 32,667 | $30K | 0.0% | N/A | 0.050% | |
| 10/24/2024 | Novo Holdings A S | 3,354,449 | $3.52M | 0.2% | -24.3% | 5.092% | |
| 8/20/2024 | Novo Holdings A S | 4,429,449 | $5.18M | 0.3% | -12.9% | 6.723% | |
| 8/15/2024 | Armistice Capital LLC | 1,545,000 | $1.81M | 0.0% | -10.4% | 2.345% | |
| 8/12/2024 | XTX Topco Ltd | 26,555 | $31K | 0.0% | +67.4% | 0.040% | |
| 8/9/2024 | Renaissance Technologies LLC | 180,800 | $0.21M | 0.0% | +8.1% | 0.274% | |
| 2/15/2024 | PFM Health Sciences LP | 2,341,107 | $4.40M | 0.3% | +73.0% | 3.554% | |
| 2/13/2024 | Stonepine Capital Management LLC | 1,666,037 | $3.13M | 1.4% | -15.7% | 2.529% | |
| 2/13/2024 | Armistice Capital LLC | 1,924,000 | $3.62M | 0.0% | -10.4% | 2.920% | |
| 11/15/2023 | Armistice Capital LLC | 2,148,000 | $3.03M | 0.0% | N/A | 3.260% | |
| 11/14/2023 | Stonepine Capital Management LLC | 1,975,308 | $2.79M | 0.9% | N/A | 2.998% | |
| 11/14/2023 | Pivotal bioVenture Partners Investment Advisor LLC | 864,197 | $1.22M | 0.5% | N/A | 1.312% | |
| 11/8/2023 | Vivo Capital LLC | 6,173,439 | $8.71M | 1.1% | +104.7% | 9.371% | |
| 7/25/2023 | Summit Trail Advisors LLC | 43,744 | $86K | 0.0% | N/A | 0.152% | |
| 2/14/2023 | RA Capital Management L.P. | 1,127,260 | $2.59M | 0.1% | -39.3% | 3.911% | |
| 11/14/2022 | Psagot Value Holdings Ltd. Israel | 40,846 | $0.11M | 0.0% | N/A | 0.142% | |
| 11/2/2022 | Victory Capital Management Inc. | 43,741 | $0.12M | 0.0% | N/A | 0.152% | |
| 2/15/2022 | Samsara BioCapital LLC | 1,120,437 | $7.17M | 1.4% | N/A | 3.888% | |
| 2/15/2022 | Capital World Investors | 1,235,000 | $8.11M | 0.0% | N/A | 4.286% | |
| 2/14/2022 | Soleus Capital Management L.P. | 672,734 | $4.31M | 0.4% | N/A | 2.335% | |
| 2/14/2022 | Novo Holdings A S | 3,277,932 | $20.98M | 1.0% | N/A | 11.376% | |
Data available starting January 2016
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
Read More on IO Biotech
Volume
1,016,008 shs
Average Volume
841,240 shs
Market Capitalization
$48.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.47
Who are the company insiders with the largest holdings of IO Biotech?
Who are the major institutional investors of IO Biotech?
Which institutional investors are selling IO Biotech stock?
Within the last quarter, IOBT stock was sold by these institutional investors:
- Novo Holdings A S
- Bank of America Corp DE
Which institutional investors are buying IO Biotech stock?
In the previous quarter, IOBT stock was purchased by institutional investors including:
- Millennium Management LLC
- Boothbay Fund Management LLC
Within the last year, these company insiders have bought IO Biotech stock:
- Holdings A/S Novo (Major Shareholder)
- Amy Sullivan (CFO)
- Mai-Britt Zocca (CEO)
Learn More investors buying IO Biotech stock.
